Patents Assigned to ADLAI NORTYE BIOPHARMA CO., LTD.
-
Patent number: 11965875Abstract: The present application relates to a system and a method for effectively screening and assessing agents for tumor immunotherapy, which includes assessment for the effects of target cells, non-target cells, and tumor infiltration. The system and method of the present application can be used to comprehensively and systematically assess the effectiveness and safety of the agent against tumor immune cells.Type: GrantFiled: May 18, 2021Date of Patent: April 23, 2024Assignee: ADLAI NORTYE BIOPHARMA CO. LTD.Inventors: Nanhai He, Youping Wang, Yang Lu, Donghui Yang
-
Publication number: 20240085425Abstract: The present disclosure provides an application of non-phosphorylated ?-catenin protein in tumor cells as a biomarker for predicting the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method of using non-phosphorylated ?-catenin protein in tumor cells as a biomarker to predict the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method for treating tumor patients, a method for detecting the content of non-phosphorylated ?-catenin in tumor tissues or tumor cells, and a suitable wnt inhibitor.Type: ApplicationFiled: August 18, 2023Publication date: March 14, 2024Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Nanhai HE, Youping WANG, Zhihong LIU, Yufeng CHEN
-
Publication number: 20240043551Abstract: Provided is an antibody or an antigen binding fragment thereof capable of specifically binding to Tumor necrosis factor receptor type 2, which comprises a VH, a VL or both, said VH comprises at least one HCDR, which comprises an amino acid sequence selected from the group consisting of the amino acid sequences as set forth in SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17. The antibody or an antigen binding fragment thereof binds strongly and specifically to TNFR2.Type: ApplicationFiled: December 10, 2021Publication date: February 8, 2024Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Yi ZHANG, Yonglin CHEN
-
Publication number: 20230399327Abstract: A compound of formula (I) having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising the compound. Also provided are the use of the compound in the prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.Type: ApplicationFiled: October 26, 2021Publication date: December 14, 2023Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Yufeng CHEN, Canfeng LIU, Meng LV, Qiaodong WEN, Yongqiang SHI, Peng WU, Kaixuan CHEN, Han YANG, Wanli CHENG, Youping WANG, Pingping LU, Nanhai HE
-
Publication number: 20230390301Abstract: Provided are a compound having the structure of formula (I) for inhibiting Wnt pathway activity, a pharmaceutical composition comprising the compound, and use of the compound in prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases, or immune-mediated diseases.Type: ApplicationFiled: October 27, 2021Publication date: December 7, 2023Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Yufeng CHEN, Peng WU, Meng LV, Canfeng LIU, Han YANG, Kaixuan CHEN, Wanli CHENG, Feifan LI, Youping WANG, Keke CHEN, Pingping LU, Nanhai HE
-
Patent number: 11680271Abstract: The present disclosure application relates to a construction method of a yeast display library (YSD), specifically to a construct for a yeast display library, an expression vector, a host cell and a construction method and use thereof. The yeast display library provided by the present application has high transformation efficiency and rich diversity.Type: GrantFiled: May 17, 2021Date of Patent: June 20, 2023Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Nanhai He, Dandan Chen, Yang Lu, Donghui Yang
-
Publication number: 20230054028Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.Type: ApplicationFiled: December 22, 2020Publication date: February 23, 2023Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Zhiyong YU, Pan LI, Beidi XU, Yu ZHOU, Wei PANG, Qiaodong WEN, Yongqiang SHI, Zhao SUN, Meng LV
-
Publication number: 20220227733Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.Type: ApplicationFiled: February 20, 2020Publication date: July 21, 2022Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Pan LI, Beidi XU, Qiaodong WEN, Enguang FENG, Ji WANG, Yang LU, Yu ZHOU, Zhiyong YU, Zhiying HUANG
-
Patent number: 11111230Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.Type: GrantFiled: June 26, 2020Date of Patent: September 7, 2021Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Pan Li, Qiaodong Wen, Ji Wang, Quan Gan, Yang Lu, Donghui Yang
-
Publication number: 20200399265Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.Type: ApplicationFiled: May 24, 2019Publication date: December 24, 2020Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Shifeng LIU, Zhiyong YU, Wei PANG, Ji WANG, Peng CHEN
